2019 Conference Agenda
Wednesday Thursday Friday
Tuesday, May 28, 2019
6:00 - 8:00 pm "Welcome to Boston"- COCKTAIL RECEPTION
Wednesday, May 29, 2019
7:15 - 8:25 am BREAKFAST
8:25 - 8:35 am Welcome | Day One Introductions and Announcements
  2019 Boston Conference Chairman: Justin Renz, President & CFO, Correvio Pharmaceuticals, Inc.
8:35 - 9:00 am KEYNOTE PRESENTATION: "Goverment and Policy" Remarks by Massachusetts Lt. Governor, Karyn Polito
  Massachusetts Lt. Governor Karyn Polito is actively involved in Governor Baker's administration's focus on promoting Life Sciences research, development and manufacturing. The Lt. Governor will lead a discussion on leadership, building consensus, resource allocation strategies and working with cross-functional groups with competing priorities.
9:00 - 10:15 am KEYNOTE PRESENTATION: "Boston's Winning Ways: The Secrets behind Massachusett's Biotech Industry"
  We will discuss the secrets behind the Massachusetts biotech industry and the various public and private-sector efforts that ensured Kendall Square would become the global hub that it is today, and the snowball effect that occurred as nearly every major life sciences company in the country raced to open here.
Assisted by:
Peter Abair, Executive Director, MassEcon
Jon Chesto, Reporter, Boston Globe. Business
10:15 -10:30 am Break
10:30 -12:00 pm KEYNOTE SPEAKER: Mike Eruzione, Captain, 1980 US Gold Medal Olympic Team, "The Road to the Gold Medal"
  Mike will talk about his and the Team’s journey leading up to the Games at Lake Placid.  His speech will relate the behind-the-scene events that took place, while stressing Teamwork, overcoming adversity, and goal setting.
12:00 - 1:15 pm LUNCH
1:15 - 2:15 pm Technical Accounting Update - Ernst & Young LLP
  Update on the latest accounting developments that are expected to impact bioscience companies. EY will share their insights on how the matters are being interpreted, what bioscience companies should be focused on, and how the various regulatory bodies view these areas.
Michael Formolo, Partner, Ernst & Young, LLP
Victoria Forward,
Partner, Assurance Services, Ernst & Young LLP
Tom Mantione, Senior Manager, Ernst & Young LLP
Michael Levy, Senior Manager, Assurance Services, Ernst & Young, LLP

  An interactive discussion of the top issues faced by commercial bioscience company CFOs. We will be focusing on the finance infrastructure to support a commercial organization, managing Wall Street expectations, drug pricing, controlling spend, tax considerations, partnership considerations and compliance.”
Iain Brown, Senior Vice President of Finance, Chief Accounting Officer, Alkermes Inc.
Manmeet Soni,
Chief Financial Officer, Alnylam Pharmaceuticals, Inc.
Jim Frates, Chief Financial Officer, Alkermes, Inc.
Michelle Robertson,
Chief Financial Officer, Momenta Pharmaceuticals
3:15 -3:30 am Break
3:30 - 4:30 pm KEYNOTE PRESENTATION: Kevin Gillis, "Private to Public Life Style Transition"
  “An Interactive Discussion on the Transition From Private to Public" The panel will focus on the activities accounting and finance departments and their companies need to prepare for and execute 6-9 months prior, 6 months after and then 12-18 months after their IPO.  The panel will discuss accounting preparedness, systems and staffing requirement and the natural  compliance and cultural evolutions that take place within an organization as it matures and grows.
Kevin Gillis, Partner, Chief Financial Officer, Third Rock Ventures
Mike Landsittel
, Chief Financial Officer, Blueprint Medicines
Yasir Al-Wakeel,
Chief Financial Officer, Neon Therapeutics, Inc.
Cindy Driscoll,
Vice President, Finance, Magenta Therapeutics, Inc.
4:30 - 5:30 pm "Cybersecurity -How does it impact the Life Science Industry?"
  Our panel of experts will discuss the digital transformation of organizations, the cyber risk impact, and this panel’s approach to proactively and reactively managing enterprise risks.
Kristin Kraeger, Managing Director, AON
Kevin Jacobsen, Executive Director, Advisory Services, Cybersecurity & Insider Threat Services, Ernst & Young LLP
James C. Trainor, Senior Vice President, AON, former Assistant Director, Cyber Division, Federal Bureau of Investigation
Lynn Martin, Senior Vice President, Engagement Lead, Global Information Security, Bank of America Merrill Lynch
5:30 - 7:00 pm Evening Social Event and Networking - Cocktail Hour, Walk to Fenway Park, Boston Red Sox vs. Cleveland Indians, game starts at 6:10 pm - Game limited to first 120 sign-ups (Waiting list for subsequent signups, in order of registration date).
Thursday, May 30
7:15 - 8:30 am BREAKFAST
8:30 - 9:00 am Welcome | Day Two Introductions and Announcements
  2020 San Diego Conference Chairman:  
9:00 - 10:15 am KEYNOTE SPEAKER: Robert Coughlin, President & CEO, Massachusetts Biotech Counsel, "My Journey as Father, Patient Advocate and CEO of MassBio"
  Bob brings passion and energy to all of his endeavors. As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them. A true winner and a champion of diversity and science, Bob will motivate you to live life to its fullest as he shares his journey as a father, Patient Advocate and CEO of MassBio.
10:15 - 10:30 am Break
10:30 - 11:30 am PANEL PRESENTATION: "A New Generation of CFOs"
  This conversation will span diversity of experience (sectors, foundational training, etc.) we are seeing across the industry, primarily driven by market demand and a supply shortage in talent. We also have quite a bit of interesting data to share regarding market dynamics.
    Moderators: Cissy S. Young,Ph.D., Managing Director, Russell Reynolds Associates
Rose Mistri-Somers, Consultant, Russell Reynolds Associates
    Pranelists: Hunter Smith, Chief Financial Officer, Rhythm Pharmaceuticals, Inc.
David A. Spellman, Chief Financial Officer, Mersana Therapeutics
Michelle Robertson,
Chief Financial Officer, Momenta Pharmaceuticals
Allan Reine, M.D.,
Chief Financial Officer, Pieris Pharmaceuticals
Tommy Leggett,
Chief Financial Officer, Axcella Health
11:30 - 12:20 pm KEYNOTE PRESENTATION: "Women in Leadership"
  Top women in the role of strategic CFO.   The interactive discussion will focus on what does it take to be a strategic partner and the top financial officer, managing the boardroom and being board ready
Sarah Larson, Partner/Chief Human Resources Officer,Third Rock Ventures
Kim Drapkin, Chief Financial Officer, Jounce Therapeutics, Inc.
Kimi Iguchi, Chief Financial Officer, Sage Therapeutics, Inc.
Pam Kelleher, Partner, Ernst & Young, LLP
12:20 - 1:15 pm LUNCH [Regional Coordinators' Meeting]
1:15 - 2:15 pm KEYNOTE SPEAKER: Solomon Wilcots, NFL Broadcaster/Leader, Russo Partners' Sports-Health Alliance, "How Preparation Eliminates Pressure"
  Finance Executives need to constantly manage and demonstrate emotional intelligence, energy and leadership. Solomon Wilcots will lead an interactive discussion on how athletes must prepare for demanding situations and support one another at all levels to achieve the team’s ultimate goal. This lecture will expand upon how these practices go beyond athletics and bridge the world of athletic competition to business to lead to success in life science companies.
  Short Break to Change Rooms
2:15 - 3:15 pm PANEL PRESENTATIONS - Select One
  A. Compensation An interactive session organized by AON that will delve into the current compensation trends in the biotechnology industry based on observations from interactions with board, management and proxy advisors. In addition, the presenters will discuss corporate governance best practices and regulatory development in compensation.
    Presenters: Lee Ownbey, Director, Radford
Ram Kumar, Associate Partner, Radford
  B. XBRL Use This presentation, overseen by Toppan Merrill, will cover how the use of XBRL is reaching a tipping point and revolutionizing how the SEC and investing community is benefiting by its use. Participants will  learn how users of this data, especially the SEC, can effectively compare filings for abnormalities, patterns, outliers, or other trends that could indicate misconduct, and give the SEC insight into issues of which a Registrant may not even be aware.
    Presenters: Mike Schlanger, Vice President, Solution Sales, Toppan Merrill
Mike Willis, Assistant Director, Office of Structured Disclosure, Division of Economics and Risk Analysis, U.S Securities and Exchange Commission
Christine Tan, Ph.D
., Chief Research Officer & Co-founder, idaciti, Inc.
  C. Financial and Resource Management - TARGETED Reporting and Dashboards - Why It Matters Timely delivery of key information to key people can be daunting. Join us to discuss "Targeted, Role Based Reporting and Dashboards." This panel discussion will address how to empower your business partners with meaningful financial data without burdening the finance organization.  Due to the automation that makes this possible, you can now expand the definition of "stakeholder," and get back to being the strategic partner Finance is supposed to be.
Wanda Ionescu, Chief Executive Officer, President, R&D Logic, Inc.
Chris Lindblom, Vice President, Finance, Treasurer, Cogen Therapeutics
Andrew Morton, Senior Diretor Financial Planning & Analysis, RA Pharmaceuticals
Karen Wright, Chief Financial Officer, Corporate Treasurer, Jaguar Health, Inc.
  Short Break to Change Rooms
3:15 - 4:15 pm COMPANY ROUNDTABLES - Select One
  These company roundtables will be facilitated by Pepper Hamilton, LLP along with carefully selected CFOs from each of the company stages with the aim of providing a forum for thoughtful discussion of the issues relevant to each.
  Early Stage Companies Whether public or private early stage life sciences companies face unique challenges in raising necessary capital and transacting with strategic partners and critical vendors.  In this roundtable, we will explore such challenges and various tactics to prepare for and succeed in the early stage. 
    Panelists: Timothy C. Atkins, Health Sciences, Partner, Pepper Hamilton LLP
Daniel Geffken, Founder and Managing Director, Danforth Advisors
Brad Smith,
Chief Financial Officer, Homology
Michael C. Diem, M.D., Senior Vice President, Amicus Therapeutics
  Late Stage Companies Our panel will focus on financing opportunities and challenges, royalty deals and M&A considerations for both public and private late stage companies. 
    Panelists: Rachel Bushey, Chair of Life Sciences, Pepper Hamilton LLP
Christopher Miller, Partner, Corporate and Securities Practice Group, Pepper Hamilton LLP
Douglas R. Carlson,
Chief Financial Officer, Kyn Therapeutics
  Commercialized Companies "Preparing for Commercialization—The Dos and Don’ts"
  • Preparing Marketing Materials
  • Interactions with Health Care Providers
  • Pulling it altogether – Elements of Compliance Plan
  • Acquisition/Exit – Compliance Red flags

    Panelists: Barry Boise, Health Sciences, Partner, Pepper Hamilton LLP
Mike Celano, Chairman of the Board, Orasure Technologies
4:15 - 4:30 pm Break
4:30 -5:30 pm PANEL PRESENTATION - "Making Optimal R&D Investment Decisions - EY Parthenon"
  How do biotechnology executive teams make optimal R&D investment decisions in a rapidly changing environment involving next generation technologies, small population disease areas and significant levels of pricing pressures from various stakeholders?
Specific discussion topics will include:
  • How is the investment considerations different for assets targeting rare diseases vs large populations?
  • For next generation therapies (gene therapy, modified cell therapies etc…), what are some of the important considerations?
  • What does the future hold for next generation therapies? And how will current pharmaceutical models need to evolve?
Jeff Stoll - Partner, Life Sciences, EY Parthenon, Ernst & Young LLP
Peter Ray, Vice President, Strategy, Alnylam
Daniel Rosan, Sr. Director of R&D Business Operations, Biogen
  15 Minute Break Before Evening Special Event
5:45 pm Thursday Evening Special Event - Buses to leave at 5:45 pm
Friday, May 31, 2019
7:15 - 8:45 am BREAKFAST
8:45 - 9:00 am Welcome | Day Three Introductions and Announcements
2019 Boston Conference Chairman: Justin Renz, President & CFO, Correvio Pharmaceuticals, Inc.
9:00 - 10:15 am KEYNOTE SPEAKER: Joseph Quinlan, Managing Director & Chief Market Strategist, US Trust, Bank of America, Private Wealth Management
  The US economic expansion continues, the bull market in equities lives on. But for how long? Joe’s presentation will highlight key drives of growth, critical secular trends, and the potential risks to growth and earnings in the medium-term. Key global trends affecting the US economy and capital markets will also be examined.
10:15 - 11:15 am PANEL PRESENTATION: "Beyond the C-Suite"
  This session will address how to prepare CFOs to move beyond the finance function and into broader roles in addition to the Boardroom. Our panelists will be a number of individuals who have successfully transitioned into CBO/COO/CEO roles from Finance, in addition to sitting CFOs who serve on Boards today.

Cissy S. Young, Ph.D., Managing Director, Russell Reynolds Associates
Rose Mistri-Somers, Consultant, Russell Reynolds Associates
Frank Thomas, Chief Financial Officer, Chief Business Officer, Orchard Therapeutics
Gina Consylman, Chief Financial Officer, Ironwood Pharmaceuticals, Board Member, Versastem
Eric Shaff, President and Chief Executive Officer, Seres Therapeutics
Rick Shea, Chief Financial Officer, Syndax Pharmaceuticals, Board Member, Synlogic
Meryl Zausner, Baord of Directors, Chair, Audit Committee, Neon Therapeutics; Audit Committee, Seres Therapeutics
Jim Frates, Chief Financial Officer, Alkermes, Booard of Directors, Sage Therapeutics, Trustee, Roxbury Latin School
11:15 am Conference Concludes
Back to Top